Cohen Klingenstein LLC Biogen Inc. Transaction History
Cohen Klingenstein LLC
- $2.83 Billion
- Q4 2024
A detailed history of Cohen Klingenstein LLC transactions in Biogen Inc. stock. As of the latest transaction made, Cohen Klingenstein LLC holds 4,000 shares of BIIB stock, worth $575,720. This represents 0.02% of its overall portfolio holdings.
Number of Shares
4,000
Previous 4,000
-0.0%
Holding current value
$575,720
Previous $775,000
21.16%
% of portfolio
0.02%
Previous 0.03%
Shares
1 transactions
Others Institutions Holding BIIB
# of Institutions
998Shares Held
130MCall Options Held
1.12MPut Options Held
1.43M-
Vanguard Group Inc Valley Forge, PA16.7MShares$2.4 Billion0.06% of portfolio
-
Primecap Management CO Pasadena, CA16.3MShares$2.35 Billion2.37% of portfolio
-
Black Rock Inc. New York, NY14.5MShares$2.09 Billion0.08% of portfolio
-
State Street Corp Boston, MA7.34MShares$1.06 Billion0.06% of portfolio
-
Jpmorgan Chase & CO New York, NY5.26MShares$757 Million0.08% of portfolio
About BIOGEN INC.
- Ticker BIIB
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 144,000,992
- Market Cap $20.7B
- Description
- Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...